Delivery of gene silencing agents for breast cancer therapy

Breast Cancer Research

Volumn 15, Issue 3, 2013, Pages

  Shen, Haifa ^a,b   Mittal, Vivek ^b   Ferrari, Mauro ^a,b   Chang, Jenny ^a,b  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; DOCETAXEL; DOXORUBICIN; MICRORNA; PACLITAXEL; SHORT HAIRPIN RNA; SMALL INHIBITORY RNA; SMALL INTERFERING RNA; SMALL NONCODING MICRORNA; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; NANOTECHNOLOGY; NONHUMAN; OVARY CANCER; RNA INTERFERENCE; THERAPY RESISTANCE; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); FEMALE; GENE THERAPY; GENE TRANSFER; GENETICS; PATHOLOGY;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; GENE SILENCING; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; MICRORNAS; RNA INTERFERENCE;

EID: 84877650524     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3413     Document Type: Article

References (52)

1. Cantley LC, Dalton WS, DuBois RN, Finn OJ, Futreal PA, Golub TR, Hait WN, Lozano G, Maris JM, Nelson WG, Sawyers CL, Schreiber SL, Spitz MR, Steeg PS. AACR Cancer Progress Report 2012. Clin Cancer Res 2012, 18(21 Suppl):S1-100.
2. Fauman EB, Rai BK, Huang ES. Structure-based druggability assessment-identifying suitable targets for small molecule therapeutics. Curr Opin Chem Biol 2011, 15:463-468. 10.1016/j.cbpa.2011.05.020, 21704549.
3. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811. 10.1038/35888, 9486653.
4. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498. 10.1038/35078107, 11373684.
5. Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ, Zhao Z, Smogorzewska A, Sowa ME, Ang XL, Westbrook TF, Liang AC, Chang K, Hackett JA, Harper JW, Hannon GJ, Elledge SJ. Cancer proliferation gene discovery through functional genomics. Science 2008, 319:620-624. 10.1126/science.1149200, 2981870, 18239126.
6. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113. 10.1126/science.1145720, 17932254.
7. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402. 10.1016/j.ccr.2007.08.030, 17936563.
8. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635-647. 10.1016/j.cell.2005.01.014, 15766527.
9. Han M, Liu M, Wang Y, Chen X, Xu J, Sun Y, Zhao L, Qu H, Fan Y, Wu C. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One 2012, 7:e39520. 10.1371/journal.pone.0039520, 3382593, 22761812.
10. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T, Parenti AR, Daidone MG, Bicciato S, Piccolo S. A microRNA targeting dicer for metastasis control. Cell 2010, 141:1195-1207. 10.1016/j.cell.2010.05.017, 20603000.
11. Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Menard S, Croce CM, Tagliabue E. microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009, 69:2195-2200. 10.1158/0008-5472.CAN-08-2920, 19276373.
12. Adachi R, Horiuchi S, Sakurazawa Y, Hasegawa T, Sato K, Sakamaki T. ErbB2 down-regulates microRNA-205 in breast cancer. Biochem Biophys Res Commun 2011, 411:804-808. 10.1016/j.bbrc.2011.07.033, 21787752.
13. Ferrari M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol 2010, 28:181-188. 10.1016/j.tibtech.2009.12.007, 2843761, 20079548.
14. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C, CAELYX Breast Cancer Study Group Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15:440-449. 10.1093/annonc/mdh097, 14998846, CAELYX Breast Cancer Study Group.
15. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001, 19:1444-1454.
16. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794-7803. 10.1200/JCO.2005.04.937, 16172456.
17. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001, 41:189-207. 10.1016/S0065-2571(00)00013-3, 11384745.
18. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005, 15:102-111. 10.1016/j.gde.2004.12.005, 15661540.
19. Fenske DB, Cullis PR. Liposomal nanomedicines. Expert Opin Drug Deliv 2008, 5:25-44. 10.1517/17425247.5.1.25, 18095927.
20. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Rohl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441:111-114. 10.1038/nature04688, 16565705.
21. Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, Bacallado SA, Nguyen DN, Fuller J, Alvarez R, Borodovsky A, Borland T, Constien R, de Fougerolles A, Dorkin JR, Narayanannair Jayaprakash K, Jayaraman M, John M, Koteliansky V, Manoharan M, Nechev L, Qin J, Racie T, Raitcheva D, Rajeev KG, Sah DW, Soutschek J, Toudjarska I, Vornlocher HP, Zimmermann TS, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008, 26:561-569. 10.1038/nbt1402, 3014085, 18438401.
22. Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MM, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AK. Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res 2011, 17:1713-1721. 10.1158/1078-0432.CCR-10-2081, 3077122, 21300758.
23. Monteagudo S, Perez-Martinez FC, Perez-Carrion MD, Guerra J, Merino S, Sanchez-Verdu MP, Cena V. Inhibition of p42 MAPK using a nonviral vectordelivered siRNA potentiates the antitumor effect of metformin in prostate cancer cells. Nanomedicine (Lond) 2012, 7:493-506. 10.2217/nnm.11.61, 21995500.
24. Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A, Elgueta R, Wang L, Nesbeth Y, Durant Y, Gewirtz AT, Sentman CL, Kedl R, Conejo-Garcia JR. Polyethylenimine-based siRNA nanocomplexes reprogram tumorassociated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 2009, 119:2231-2244. 2719935, 19620771.
25. Navarro G, Sawant RR, Biswas S, Essex S, Tros de Ilarduya C, Torchilin VP. P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Nanomedicine (Lond) 2012, 7:65-78. 10.2217/nnm.11.93, 3422569, 22191778.
26. Lee JB, Hong J, Bonner DK, Poon Z, Hammond PT. Self-assembled RNA interference microsponges for efficient siRNA delivery. Nat Mater 2012, 11:316-322. 10.1038/nmat3253, 22367004.
27. Yao YD, Sun TM, Huang SY, Dou S, Lin L, Chen JN, Ruan JB, Mao CQ, Yu FY, Zeng MS, Zang JY, Liu Q, Su FX, Zhang P, Lieberman J, Wang J, Song E. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci Transl Med 2012, 4:130ra148.
28. Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, Ambegia E, McClintock K, MacLachlan I. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009, 119:661-673. 10.1172/JCI37515, 2648695, 19229107.
29. Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, Sah DW, Stebbing D, Crosley EJ, Yaworski E, Hafez IM, Dorkin JR, Qin J, Lam K, Rajeev KG, Wong KF, Jeffs LB, Nechev L, Eisenhardt ML, Jayaraman M, Kazem M, Maier MA, Srinivasulu M, Weinstein MJ, Chen Q, Alvarez R, Barros SA, De S, Klimuk SK, Borland T, Kosovrasti V, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010, 28:172-176. 10.1038/nbt.1602, 20081866.
30. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, Dames S, Loffler K, Fechtner M, Arnold W, Giese K, Klippel A, Kaufmann J. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 2006, 13:1222-1234. 10.1038/sj.gt.3302777, 16625243.
31. Unsal-Kacmaz K, Ragunathan S, Rosfjord E, Dann S, Upeslacis E, Grillo M, Hernandez R, Mack F, Klippel A. The interaction of PKN3 with RhoC promotes malignant growth. Mol Oncol 2012, 6:284-298. 10.1016/j.molonc.2011.12.001, 22217540.
32. ClinicalTrials.gov: Study With Atu027 in Patients With Advanced Solid Cancer. , http://www.clinicaltrials.gov/ct2/show/NCT00938574?term=atu027&rank = 1
33. Landen CN, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005, 65:6910-6918. 10.1158/0008-5472.CAN-05-0530, 16061675.
34. Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther 2009, 8:1027-1034. 10.4161/cbt.8.11.8523, 2748749, 19395869.
35. ClinicalTrials.gov: EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery. , http://www.clinicaltrials.gov/ct2/show/NCT01591356?term=EphA2&rank = 1
36. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070. 10.1038/nature08956, 2855406, 20305636.
37. Bellocq NC, Pun SH, Jensen GS, Davis ME. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem 2003, 14:1122-1132. 10.1021/bc034125f, 14624625.
38. Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res 2013, 19:1806-1815. 10.1158/1078-0432.CCR-12-2764, 23386691.
39. Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM, Lopez-Berestein G, Sood AK, Ferrari M. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 2010, 70:3687-3696. 10.1158/0008-5472.CAN-09-3931, 3202607, 20430760.
40. van de Ven AL, Kim P, Haley O, Fakhoury JR, Adriani G, Schmulen J, Moloney P, Hussain F, Ferrari M, Liu X, Yun SH, Decuzzi P. Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J Control Release 2011, 158:148-155. 3422657, 22062689.
41. Godin B, Tasciotti E, Liu X, Serda RE, Ferrari M. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res 2011, 44:979-989. 10.1021/ar200077p, 3204797, 21902173.
42. Xu R, Huang Y, Mai J, Zhang G, Guo X, Xia X, Koay EJ, Qin G, Erm DR, Li Q, Liu X, Ferrari M, Shen H. Multistage vectored siRNA targeting ataxiatelangiectasia mutated for breast cancer therapy. Small 2013,
43. Ferrari M. Vectoring siRNA therapeutics into the clinic. Nat Rev Clin Oncol 2010, 7:485-486. 10.1038/nrclinonc.2010.131, 20798696.
44. MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, Sedliarou I, Wetzel S, Kochar K, Brahmbhatt VN, Phillips L, Pattison ST, Petti C, Stillman B, Graham RM, Brahmbhatt H. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol 2009, 27:643-651. 10.1038/nbt.1547, 19561595.
45. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008, 100:672-679. 10.1093/jnci/djn123, 18445819.
46. Dave B, Landis MD, Dobrolecki LE, Wu MF, Zhang X, Westbrook TF, Hilsenbeck SG, Liu D, Lewis MT, Tweardy DJ, Chang JC. Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One 2012, 7:e30207. 10.1371/journal.pone.0030207, 3412855, 22879872.
47. Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, Petrelli NJ, Dunn SP, Krueger LJ. MicroRNA let-7a down-regulates MYC and reverts MYCinduced growth in Burkitt lymphoma cells. Cancer Res 2007, 67:9762-9770. 10.1158/0008-5472.CAN-07-2462, 17942906.
48. Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y, McCue PA, Quong AA, Lisanti MP, Pestell RG. microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci USA 2010, 107:8231-8236. 10.1073/pnas.1002080107, 2889540, 20406904.
49. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008, 10:593-601. 10.1038/ncb1722, 18376396.
50. Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 2007, 21:1132-1147. 10.1210/me.2007-0022, 17312270.
51. Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C, Iorio MV, Li M, Volinia S, Alder H, Nakamura T, Nuovo G, Liu Y, Nephew KP, Croce CM. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst 2010, 102:706-721. 10.1093/jnci/djq102, 2873185, 20388878.
52. Ryu S, McDonnell K, Choi H, Gao D, Hahn M, Joshi N, Park SM, Catena R, Do Y, Brazin J, Vahdat LT, Silver RB, Mittal V. Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration. Cancer Cell 2013, 23:63-76. 10.1016/j.ccr.2012.11.019, 23328481.